Sub menu

Vaccines

Comirnaty Omicron XBB.1.5 >12 years (dark grey cap) formulation

Details for Comirnaty Omicron XBB.1.5 >12 years (dark grey cap) formulation vaccine and its components.

Recently added

This page was added on 22 November 2023.

Updates made

This page was updated on [date-counter-updated-date]. View history of updates

Sponsor
Pfizer Australia
Administration route
Intramuscular injection
Vaccine group
Adolescent and adult formulations
Description:

Registered for use in people aged >12 years 

COVID-19 vaccine containing nucleoside-modified mRNA encoding the spike glycoproteins of SARS-CoV-2 Omicron XBB.1.5 strain.  

Multidose vial without preservative. Each vial contains 6 doses in 2.25mL. Does not require dilution.  

Each 0.3 mL dose contains: 

  • 30 µg mRNA encoding the SARS-CoV-2 Omicron XBB.1.5 spike glycoprotein  
  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) 
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)  
  • Distearoylphosphatidylcholine (DSPC)  
  • Cholesterol  
  • Trometamol  
  • Trometamol hydrochloride  
  • Sucrose  
  • Water for injections

For Product Information and Consumer Medicine Information about Comirnaty Omicron XBB.1.5 >12 years (dark grey cap) formulation visit the Therapeutic Goods Administration website.

Additional vaccine information

For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Related diseases
COVID-19

Page history

Last updated
Last reviewed

Help us improve the Australian Immunisation Handbook

Printed content may be out of date. For up to date information, always refer to the digital version:

https://immunisationhandbook.health.gov.au/vaccines/comirnaty-omicron-xbb15-12-years-dark-grey-cap-formulation

All vaccines

Link copied

Link, share or bookmark directly to this section of the page.